A pair of researchers from Iran claim they are among the few in the world to have developed a unique blood-clotting agent.
Iran’s semi-official Fars news agency said in a Monday report that Roya Salehi and Mehdi Edalati had obtained the regulatory approval for STAgel©, their novel treatment for blood-clotting processes.
The pair, from the Tabriz University of Medical Sciences (TBZMED), located in northwestern Iran, claimed their treatment would be a blockbuster that could prove more efficacious than products developed by three international companies that largely control the market for blood-clotting agents.
Blood-clotting agents are used to close wounds in emergency departments or during surgeries to prevent life-threatening complications, including blood loss, tissue damage, infection and excessive scarring.
Salehi and Edalati said STAgel© was developed after nearly five years of work, including research on how the drug could act quicker by activating several hemostatic reactions in the body.
“The prototype developed by us can simultaneously act through several hemostatic paths to control bleeding in the shortest time possible and with highest efficacy,” said the pair.
STAgel© was registered in April under the Iranian patent number 101771, said the doctors who added that they would soon commercialize the treatment in the forms of powder, pad and adhesive bandage to help boost supplies of blood-clotting agents in the country as it struggles to access medicines from abroad because of US sanctions.
Thanks to a growing government support for its home-grown medical sector, Iran has become a major manufacturer of various drugs, including biotech treatments.
Iranian biomedicine companies have become increasingly active in regional and international markets by introducing novel treatments for various ailments.
Tapping the domestic resources of drugs and medical equipment has been a major part of Iran’s efforts to tackle one of the largest outbreaks of the coronavirus pandemic in the Middle East.
Government authorities have announced they would largely rely on Iranian-made coronavirus vaccines to inoculate the country’s large population.